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Abstract	
	
Objective		
To	 investigate	 the	 clinical	 and	 pathological	 trends	 over	 a	 ten-year	 period	 for	 robotic-assisted	
laparoscopic	prostatectomy	(RALP)	in	a	UK	regional	tertiary	referral	centre.	
	
Patients	and	Methods	
1500	consecutive	patients	underwent	RALP	between	October	2005	and	January	2015.	Prospective	
data	was	collected	on	clinic-pathological	details	at	presentation	as	well	as	surgical	outcomes	and	
compared	over	time.	
	
Results	
The	median(range)	age	of	patients	throughout	the	period	was	62(35-78)	years.	The	proportion	of	
pre-operative	high-grade	cases	(Gleason	sum	8-10)	rose	from	4.6%	in	2005-2008	to	18.2%	in	2013-
2015	(p<0.0001).	 In	the	same	periods	the	proportion	of	clinical	stage	T3	cases	operated	on	rose	
from	2.4%	to	11.4%	(p<0.0001).	Median	PSA	at	diagnosis	did	not	alter	significantly.	Overall	11.6%	
of	men	 in	 2005-2008	were	 classified	 pre-operatively	 as	 high-risk	 by	 NICE	 criteria,	 compared	 to	
33.6%	in	2013-2015	(p<0.0001).	The	corresponding	proportions	for	low-risk	cases	were	48.6%	and	
17.3%	respectively.	 Final	 surgical	pathology	demonstrated	an	 increase	 in	 tumour	 stage,	Gleason	
grade	and	nodal	status	across	time.	The	proportion	of	pT3	cases	rose	from	43.2%	in	2005-2008	to	
55.5%	 in	 2013-15	 (p=0.0007),	 Gleason	 grade	 9-10	 tumours	 increased	 from	 1.8%	 to	 9.1%	
(p=0.0002)	and	positive	nodal	status	increased	from	1.6%	to	12.9%	(p<0.0001)	between	the	same	
periods.	 Despite	 this,	 positive	 surgical	margin	 rates	 showed	 a	 downward	 trend	 in	 all	 pT	 groups	
across	the	different	eras	(p=0.72).		
	
Conclusion	
This	 study	 suggests	 that	 the	 patient	 profile	 for	 RALP	 in	 our	 unit	 is	 changing,	 with	 increasing	
proportions	of	higher-stage	and	more	advanced	disease	being	referred	and	operated	on.	Surgical	
margin	outcomes	however	have	remained	good.	
	
	
	
	
	
	 	
  
	
Introduction	
	
Prostate	 cancer	 (PCa)	 is	 the	most	 common	malignancy	 in	men	and	 is	 a	 leading	 cause	of	 cancer	
related	morbidity	[1,	2].	Since	the	introduction	of	prostate-specific	antigen	(PSA)	testing	in	the	late	
1980s	there	has	been	a	steady	migration	toward	lower	stage	and	grade	disease[3].	However,	the	
trade-off	 from	 this	migration	was	 substantial	over-diagnosis	and	over-treatment	of	 cancers	 that	
may	not	have	caused	harm.	Appreciation	of	this	potential	downside	has	gradually	 led	to	a	more	
conservative	approach	 in	 the	treatment	of	 low-risk	disease.	As	a	result	surgery,	as	well	as	other	
radical	 treatment	 options,	 is	 increasingly	 reserved	 for	 patients	 with	 intermediate	 and	 high-risk	
disease	[4].	Over	the	past	decade	there	has	been	a	demonstrable	shift	in	the	management	of	PCa	
in	the	UK	with	increasing	use	of	surgery	for	younger	patients	with	high-risk	disease	[4,	5].	In	the	US	
literature,	where	the	robotic	approach	is	better-established,	a	‘reverse	stage	migration’	has	been	
demonstrated	 in	 prostatectomy	 cohorts	with	 centres	 such	 as	Memorial-Sloan	Kettering	 	 Cancer	
Centre	 reporting	 the	 proportion	 of	 men	 undergoing	 radical	 prostatectomy	 for	 low-risk	 disease	
progressively	decreasing	between	2000	and	2010[6].	It	is,	however,	not	known	whether	there	has	
been	 a	 similar	migration	 towards	 operative	 intervention	 in	 those	with	 higher-risk	 disease	 in	UK	
surgical	centres.		
	
Since	 the	 cancer	 Improving	 Outcome	 Guidelines	 in	 2002,	 the	 surgical	management	 of	 prostate	
cancer	 in	 the	 UK	 has	 largely	 been	 centralised.	 As	 a	 result,	 referral	 and	 treatment	 patterns	 are	
commonly	reflective	of	practice	across	a	wider	geographical	region	rather	than	just	one	hospital,	
particularly	as	cases	are	discussed	in	a	regional	multidisciplinary	team.		Here	we	present	case	mix	
and	 outcome	 trends	 over	 a	 10-year	 period	 from	 one	 UK	 tertiary	 referral	 centre.	 Our	 primary	
interest	was	to	evaluate	the	evolution	of	a	prostatectomy	service,	focusing	on	stage	migration	and	
its	impact	on	oncological	outcomes.		
	
	
Patients	and	Methods	
	
Study	cohort	
	
From	2005	 onwards	 patients	who	 underwent	 robotic	 radical	 prostatectomy	 at	 our	 centre	were	
recruited	into	an	ethically	approved	prospective	study	(MREC	01/4/061).	Our	centre	is	one	of	two	
  
providing	a	 tertiary	 referral	 service	 to	 the	Anglia	Cancer	Network	 covering	a	population	of	2.63	
million	people	and	including	9	hospitals	trusts.	
	
All	 patients	who	underwent	RALP	 surgery	 from	October	2005	until	 January	2015	were	 included	
with	the	exception	of	men	who	underwent	salvage	RALP.	Pre-operative	demographic	data,	biopsy	
details,	 clinical	 stage	 and	 PSA	 level	 at	 diagnosis	 were	 recorded	 prospectively	 for	 each	 patient.	
Pathological	 results	 and	 subsequent	 outcome	 data	was	 recorded	 for	 all	 cases.	 	 	 	 The	 operative	
technique	 applied	 has	 been	 described	 in	 detail	 previously.[7]	 All	 cases	 were	 operated	 on	 by	 a	
consultant	 urologist	who	had	 received	 structured	modular	 training	 (DEN,	NCS,	 VJG).	 During	 the	
series	 the	 technique	 has	 been	 modified	 slightly,	 with	 the	 addition	 of	 extended	 lymph	 node	
dissection	 (including	external	 iliac,	obturator	and	 internal	 iliac	 lymph	nodes)	 for	 intermediate	 to	
high-risk	disease	from	case	450	onwards.	Patients	were	stratified	according	to	date	of	operation	
into	 four	 era	 groups:	 2005-2008,	 2009-2010,	 2011-2012	 and	 2013-2015.	 Patients	 were	 also	
stratified	 according	 to	 2014	 NICE	 risk	 groups:	 low-risk	 (T1-T2a	 and	 GS	 ≤6	 and	 PSA	 ≤10),	
intermediate-risk	(T2b	and/or	GS	=7	and/or	PSA	>10–20),	or	high-risk	(≥T2c	or	PSA	>20	or	GS	8–
10).[8]		
	
Pre-operative	 core-biopsy	 specimens	 and	 RALP	 specimens	 were	 examined	 by	 histopathologists	
with	 a	 special	 interest	 in	 uropathology	 and	 were	 subsequently	 reviewed	 in	 the	 Uro-Oncology	
Specialist	MDT.	Pathological	processing	of	the	surgical	specimens	has	not	changed	over	the	course	
of	 the	 study	 and	 included	 4-5mm	 sectioning	 and	 processing	 of	 the	 entire	 surgical	 specimen	
according	 to	 standard	methodology.	 The	 Seventh	 edition	 of	 the	 American	 Joint	 Committee	 on	
Cancer	tumor-lymph	node	(LN)-metastasis	classification	was	used	to	define	stage.	Histopathologic	
grading	 was	 performed	 according	 to	 the	 International	 Society	 of	 Urological	 Pathology	 2005	
modification	of	 the	Gleason	 system[9].	A	positive	 surgical	margin	 (PSM)	 is	defined	as	malignant	
cells	 in	direct	contact	with	the	 inked	surface	as	reported	by	the	uro-pathologist	and	reviewed	in	
the	 MDT[10].	 Biochemical	 recurrence	 (BCR)	 was	 defined	 as	 a	 confirmed	 	 PSA	 value	 of	
>0.2ng/ml[11].		
	
Statistical	analysis	
	
Data	processing	and	descriptive	statistical	analysis	was	performed	using	MS	Excel	2013	(Microsoft,	
Redmond,	Washington,	 USA).	 Statistical	 analysis	 was	 performed	 in	 StatsDirect	 (StatsDirect	 Ltd,	
  
England,	 UK).	 ANOVA	 was	 used	 to	 look	 at	 mean	 differences	 between	 four	 groups.	 Chi	 square	
analysis	was	used	to	assess	difference	of	distributions	in	numbers	or	proportions	between	groups.	
In	tables	1	and	2	probability	values	relate	to	chi	square	analysis	between	all	4	groups,	in	the	text	
values	refer	to	direct	analysis	between	the	earliest	and	 latest	era	groups.	p	values	are	therefore	
‘chi	square	p	values,’	a	p	value	<0.05	was	considered	statistically	significant.	
	
	 	
  
Results	
	
1500	 patients	 were	 included	 in	 the	 study.	 Over	 the	 course	 of	 the	 study	 the	 annual	 caseload	
increased	 from	 51	 in	 2006	 to	 over	 200	 cases	 annually	 from	 2009	 onwards.	 There	 were	 no	
conversions	 to	 open	 surgery	 however	 there	were	 3	 cases	where	 the	 robotic	 approach	was	 not	
feasible	due	 to	 adhesions,	 pubic	 symphysis	 exostosis	 and	 intolerance	of	 Trendelenburg	position	
and	all	patients	were	treated	by	radiotherapy.		
	
Pre-operative	clinico-pathological	characteristics	 	
Baseline	patient	characteristics	according	to	time	period	are	listed	in	Table	1.	The	mean	age	across	
the	entire	cohort	was	61.5	(range	35-78)	years;	there	was	no	statistically	significant	difference	in	
age	between	the	populations	 in	 the	 four	era	 (p=0.91).	Overall,	 the	mean	pre-operative	PSA	was	
8.5	 (range	 0.5-89)	 ng/mL;	 there	 were	 no	 statistically	 significant	 differences	 in	 the	 PSA	 levels	
between	eras	 (p=0.10).	With	 regards	 to	 the	pre-treatment	 clinical	 stage,	 there	were	 statistically	
significant	 differences	 over	 time,	 with	 the	 proportion	 of	 cT1	 tumours	 declining	 from	 64.4%	 in	
2005-8	to	45.9%	in	the	most	recent	era	(p<0.0001).	In	parallel,	there	was	a	significant	increase	in	
the	proportion	of	higher	clinical	stage	tumours,	with	cT3	representing	2.4%	of	pre-operative	cases	
in	2005-8	as	compared	to	11.4%	in	2013-5	(p<0.0001).	An	upward	trend	was	also	noted	in	the	pre-
operative	Gleason	score	over	time	(Table	1).	More	specifically,	the	proportion	of	Gleason	sum	≥8	
increased	 from	 4.6%	 to	 18.2%	 between	 the	 periods	 of	 2005-8	 and	 2013-15.	 	 Similarly,	 pre-
operative	 NICE	 Risk	 Group	 also	 changed	 over	 the	 series	 with	 the	 proportion	 of	 patients	 pre-
operatively	defined	as	high-risk	disease	 increasing	 from	11.6%	to	33.6%	between	 the	periods	of	
2005-8	and	2013-15	(p	<0.0001).	
	
Surgical	pathology	outcomes	
Table	2	demonstrates	the	final	pathological	characteristics	of	the	resected	prostates	including	the	
PSM	rates	for	each	era.	In	3	cases,	no	tumour	was	found	on	the	final	pathological	analysis	(pT0),	
although	1	case	demonstrated	HGPIN.	The	pre-operative	biopsies	were	re-reviewed	in	each	case,	
to	confirm	presence	of	carcinoma.	The	proportion	of	final	Gleason	3+3=6	tumours	decreased	from	
38.6%	in	2005-8	to	11.1%	in	2013-15	(p<0.0001)	whereas	the	proportion	of	Gleason	9-10	tumours	
increased,	 from	 1.8%	 to	 9.1%	 (p<0.0001)	 between	 the	 same	 periods.	 Across	 all	 eras,	 the	 final	
pathology	 in	 the	majority	of	 cases	 revealed	Gleason	7	disease.	With	 regards	 to	 the	pathological	
stage	there	was	a	reduction	in	the	proportion	of	pT2a	tumours	over	time	from	36.8%	in	2005-8	to	
  
5.5%	in	2013-15	but	a	concomitant	increase	in	pT2c	cases	from	16.1%	to	37.1%	(p<0.0001)	(Table	
2).	The	overall	proportion	of	pT3a	cases	was	 stable	 (38.0%	2005-2008	and	43.9%	 in	2013-2015)	
(p=0.102)	however	 the	proportion	of	pT3b	 tumours	 increased	 from	5.2%	 to	11.6%	between	 the	
same	dates	(p<0.0001).	No	significant	change	in	overall	PSM	rates	was	observed	across	the	series	
over	time	(p=0.72).	When	analysed	by	individual	tumour	stage,	PSM	rates	were	reduced	for	each	
category	but	did	not	reach	statistical	significance.	In	pT2	disease	PSM	rates	differed	from	11.96%	
in	2005-8	 to	6.28%	 in	2013-15	 (P=0.06).	 In	 the	same	2	periods,	PSM	rates	 in	pT3a	disease	were	
31.2%	and	25.9%	respectively	(p=0.91)	and	in	pT3b	disease	64.7%	and	43.1%	(p=	0.60).	Overall	pT3	
PSM	rates	were	35.2%	in	2005-8	and	29.5%	in	2013-15	(p=0.24).	Finally,	we	did	also	analyse	lymph	
node	involvement	 in	our	study.	Of	the	total	number	of	patients,	1033	(68.9%)	underwent	 lymph	
node	dissection	(LND).	Pathological	evidence	of	LN	involvement	increased	by	era	(Table	2).	There	
were	significant	differences	in	the	incidence	of	metastasis	in	the	LN.	With	only	1.6%	of	those	who	
underwent	 LND	 in	 2005-8	 found	 to	 have	metastasis	 compared	 to	 12.9%	 in	 2013-5	 (P<0.0001).	
However	we	 interpret	 this	with	 caution	 given	 the	 changes	 in	 lymph	 node	 dissection	 usage	 and	
extent	across	the	series.		
	
Surgical	outcomes	
There	 were	 two	 peri-operative	 mortalities	 in	 this	 series,	 one	 man	 of	 myocardial	 infarction	 in	
theatre	 recovery,	 and	 a	 second	 dying	 at	 home	 on	 day	 13	 post-operation	 from	 a	 presumed	
pulmonary	 embolism.	 Follow-up	 and	 BCR	 data	 was	 available	 for	 1358	 (90.5%)	 men,	 with	 a	
mean(range)	 follow	 up	 of	 36.1(0-97)	 months.	 92	 men	 were	 excluded	 as	 they	 underwent	
immediate	 adjuvant	 radiation	 therapy.	 Overall	 114	 patients	 (8.4%)	 developed	 BCR	 during	 the	
follow-up	 period,	 this	 was	 associated	 with	 pathological	 tumour	 stage,	 with	 5.98%	 of	 pT2	 and	
22.1%	 of	 pT3b	 patients	 experiencing	 BCR	 (p<0.0001).	 	 The	 follow-up	 is	 insufficient	 to	 draw	
conclusions	on	long-term	outcomes	but	initial	1-year	BCR	rates	are	encouraging	at	3.9%,	2.4%	and	
3.4%	for	the	first	3	eras.		
	
	
	
	
	
	
	
  
Discussion	
	
In	the	UK	there	has	been	a	significant	increase	in	the	use	of	surgery	for	intermediate	and	high	risk	
PCa	since	the	1990s	despite	a	lack	of	randomised	evidence	to	suggest	efficacy	when	compared	to	
other	 forms	 of	 treatment	 [4,	 5,	 12,	 13].	 Data	 from	 large	 observational	 cohort	 studies	 have	
suggested	 that	 surgery	 may	 improve	 outcomes	 in	 men	 with	 localised	 disease	 but	 this	 is	 most	
evident	 in	 younger	 patients	 with	 higher	 risk	 disease	 [14,	 15].	 Work	 from	 our	 own	 centre	 also	
suggests	 that	 this	 may	 be	 true	 in	 a	 UK	 	 population	 [4].	 In	 a	 study	 of	 over	 4700	men,	 surgery	
appeared	to	provide	superior	cancer	specific	mortality	outcomes	but	specifically	 in	younger	men	
and	with	high-risk	disease.	These	data	are	also	supported	by	national	opinions	on	radical	therapy	
usage	from	UK	urologists	and	oncologists	[16].	As	our	unit’s	practice	is	based	on	a	regional	referral	
structure,	it	is	likely	to	be	indicative	of	the	preferences	and	opinions	of	prostate	cancer	specialists	
from	a	number	of	different	hospital.	Our	 results	have	suggested	evidence	 for	an	 increase	 in	 the	
proportion	of	preoperative	high-risk	patients	undergoing	surgery	and	a	concomitant	fall	in	number	
of	cases	referred	with	low-risk	disease.	Although	we	did	not	observe	any	change	in	presenting	age,	
the	median	age	in	our	study	was	already	low	at	61	years.	This	is	also	reflected	in	an	increase	in	the	
final	pathologic	staging	characteristics	across	the	series.	In	the	most	recent	era,	the	proportion	of	
pT3	 disease	 was	 in	 excess	 of	 50%	 which	 is	 considerably	 higher	 than	 other	 contemporary	
international	series[17,	18].	Encouragingly,	 this	change	has	not	affected	surgical	margin	rates.	 In	
fact	we	observed	modest	trends	towards	improved	margin	free	rates	in	both	pT2	and	pT3	cases.	
The	explanation	for	this	shift	 in	tumour	characteristics	 is	 likely	to	be	multi-factorial,	 including	an	
increasing	appreciation	of	overtreatment	and	the	use	of	active	surveillance	as	a	valid	 treatment	
option.	 Another	 contributing	 factor	 is	 the	maturation	 of	 our	 robotic	 prostatectomy	 service	 and	
increased	experience	of	our	surgeons.	
	
This	 is	 the	 first	 report	 demonstrating	 this	 shift	 in	 population	 in	 a	 UK	 RRP	 series.	 Our	 findings	
however	 are	 consistent	 with	 reports	 from	 other	 high-volume	 centres.	 Bernie	 et	 al	 in	 2014	
reviewed	 their	RALP	 series	of	3451	men	 in	Houston,	USA,	and	demonstrated	an	 increase	 in	 the	
rate	 of	 high-risk	 preoperative	 and	 final	 pathologic	 disease[19].	 The	 surgical	 margin	 status	 also	
remained	 stable	 in	 their	 series	 despite	 the	 increasing	 proportion	 of	 men	 with	 pT3	 disease.	
According	to	 the	authors	 this	possibly	 reflected	the	changing	dynamics	of	 the	population	opting	
for	surgery	and	the	learning	curve	of	the	surgeons.	In	an	older	study	published	in	2011,	Silberstein	
et	al	from	Memorial	Sloan-Kettering	Cancer	Centre	evaluated	changes	in	clinical	and	pathological	
  
characteristics	 of	 patients	 treated	 surgically	 for	 localized	 PCa[6].	 The	 authors	 performed	 a	
retrospective	 review	of	 6,624	 consecutive	 patients	who	underwent	 surgery	 from	2000	 to	 2010.	
The	patients	were	stratified	according	to	the	surgical	approach	(open,	laparoscopic	and	RALP)	as	
well	 as	 according	 to	 the	 National	 Comprehensive	 Cancer	 Network	 (NCCN)	 guidelines	 risk	
categories.	 Overall,	 they	 found	 evidence	 that	 the	 proportion	 of	 patients	 who	 fell	 into	 the	
intermediate	 and	 high-risk	 categories	 increased	 during	 the	 course	 of	 the	 series,	 while	 the	
proportion	of	patients	 in	 the	 low-risk	category	decreased.	More	recently	Huland	and	Graefen	 in	
2015	reported	changing	trends	in	the	surgical	management	of	prostate	cancer	from	a	high	volume	
European	centre	over	the	past	15	years[18].	According	to	the	reported	data,	the	rate	of	 low-risk	
patients	treated	surgically	declined	from	60%	in	2004	to	27%	in	2011–2013.	Similarly,	the	rate	of	
organ-confined	disease	dropped	from	80%	to	62%	in	the	same	time	period.	The	authors	suggested	
that	 their	 findings	 reflect	 the	 better	 selection	 of	 patients	 undergoing	 surgery	 in	 contemporary	
clinical	practice,	which	minimizes	the	risk	of	over	treatment.	
	
There	are	of	course	inherent	limitations	in	our	study.	This	study	has	focused	on	those	PCa	patients	
managed	 surgically	 and	 we	 have	 not	 sought	 to	 quantify	 any	 changing	 enrollment	 to	 active	
surveillance	or	radiotherapy	which	would	predominantly	occur	at	patients’	local	hospitals,	prior	to	
referral	 for	 surgery.	We	 have	 however	 previously	 reported	 regional	 changes	 in	 trends	 for	 non-
surgical	 management	 of	 prostate	 cancer,[4]	 and	 expect	 our	 results	 reflect	 this	 increasing	
confidence	and	use	of	conservative	management.	We	have	also	not	sought	to	study	continence	or	
potency	outcomes	 in	 this	 study.	Results	 from	an	earlier	 paper	 in	 this	 cohort	 have	 already	been	
published	 and	 we	 do	 not	 yet	 have	 complete	 outcome	 data	 for	 the	 most	 recent	 men	 in	 this	
series[7].	 Our	 findings	may	 also	 not	 be	 representative	 of	 national	 trends,	 although	 there	 is	 no	
reason	 to	 expect	 significant	 differences	 in	 uptake	 of	 national	 guidelines.	 Margin	 status	 is	
associated	with	 surgical	experience	and	 therefore	we	might	expect	a	 relatively	higher	 incidence	
among	individual	surgeons.	However	in	a	recent	report,	we	observed	no	difference	in	the	SM	rates	
in	consultants	 starting	 their	 series	at	different	 time	points	 in	our	cohort[20].	 Lastly,	 longer	 term	
outcomes	are	required	to	fully	assess	the	changing	use	of	RALP	in	high-risk	patients	and	forms	part	
of	our	ongoing	data	collection.	Encouragingly,	the	number	of	men	experiencing	BCR	in	our	cohort	
was	low,	although	we	have	insufficient	follow	up	to	draw	conclusions	on	long-term	outcomes.	Few	
comparable	series	have	published	BCR	rates,	the	aforementioned	Canadian	series	report	4.9%	BCR	
rate	over	a	median	follow-up	of	18	months	[17],	whilst	an	American	series	in	2005	published	a	5%	
1-year	BCR	rate	amongst	a	lower-risk	group	[21].	
  
	 	
In	summary	this	paper	demonstrates	first	evidence	of	reverse	stage	migration	and	a	shift	toward	
operating	on	higher-risk	PCa	in	a	UK	tertiary	referral	centre.	Despite	this	change,	PSM	rates	have	
remained	 unchanged	 and	 short	 term	 BCR	 rates	 are	 encouraging.	 Our	 data	 reflect	 an	 emerging	
selection	preference	 for	 performing	 surgery	 in	men	with	 higher-risk	 disease	which	 is	 consistent	
with	evidence	of	the	oncological	efficacy	of	this	approach.	This	further	suggests	that	surgical	over-
treatment	may	be	gradually	becoming	 less	of	a	problem	 in	our	 Institution	and	very	 likely	 in	 the	
rest	of	 the	UK.	 Further	work	 should	 seek	 to	 confirm	 these	 findings	 in	other	UK	 Institutions	 and	
further	 investigation	 is	 required	 to	 evaluate	 the	 impact	 of	 this	 change	 on	 long-term	 oncologic	
outcomes.	
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Table	 1	 -Pre-operative	 characteristics	 of	 the	 cohort.	 (IQR-	 interquartile	 range,	 p	 values	 refer	 to	
comparisons	between	the	first	and	last	periods)	
	
Characteristic	 2005-2008	 2009-2010	 2011-2012	 2013-2015		 Total		 p	value		
		 n	 %/IQR	 n	 %/IQR	 n	 %/IQR	 n	 %/IQR	 n		 	%/IQR	 		
Number	of	patients	 329	 		 367	 		 364	 		 440	 		 1500	 		 		
Age	Median	(IQR)	[years]	 62	 (58,	66)	 63	 (58,	66)	 62	 (57,	66)	 62	 (57,66)	 62	 (58,	66)	 0.91	
Pre-op	PSA	Median	
[ng/ml]	 7.3	 (5.3,	10.0)	 7.3	 (5.6,	9.5)	 7.3	 (5.7,	10.1)	 7.2	 (5.3,	10.0)	 7.3	 (5.4,	10.0)	 0.1	
Clinical	stage	
	 	 	 	 	 	 	 	
		 		
	T1	 212	 64.4	 226	 61.6	 193	 53	 202	 45.9	 833	 55.5	 <0.0001	
T2a	 92	 28	 74	 20.2	 71	 19.5	 108	 24.5	 345	 23.0	 0.027	
T2b	 15	 4.6	 29	 7.9	 47	 12.9	 30	 6.8	 121	 8.1	 0.001	
T2c	 2	 0.6	 20	 5.4	 38	 10.4	 50	 11.4	 110	 7.3	 <0.0001	
T3a/T3b	 8	 2.4	 18	 4.9	 15	 4.1	 50	 11.4	 91	 6.1	 <0.0001	
Pre-op	Gleason	sum	
	 	 	 	 	 	 	 	
		 		
	≤6	 184	 55.9	 161	 43.9	 130	 35.7	 96	 21.8	 571	 38.1	 <0.0001	
7	 130	 39.5	 177	 48.2	 197	 54.1	 264	 60.0	 768	 51.2	 <0.0001	
≥8	 15	 4.6	 29	 7.9	 37	 10.2	 80	 18.2	 161	 10.7	 <0.0001	
NICE	Risk	Category	
	 	 	 	 	 	 	 	 	 	 	Low	 160	 48.6	 136	 27.2	 114	 31.3	 76	 17.3	 486	 32.4	 <0.0001	
Intermediate	 131	 39.8	 163	 44.4	 176	 48.4	 216	 49.1	 686	 45.7	 0.048	
High	 38	 11.6	 68	 18.5	 74	 20.3	 148	 33.6	 328	 21.9	 <0.0001	
	
	
	
	
  
	
Table	2	-	Final	post-operative	pathological	characteristics.		
	
Characteristic	 		2005-2008	 	2009-2010	 2011-2012	 2013-2015	 Total	 p	value	
Final	Pathology	Gleason		 n	 %	 n	 %	 n	 %	 n	 %	 n	 %	
	≤6	 127	 38.60	 113	 30.79	 86	 23.63	 49	 11.14	 375	 25.00	 <0.0001	
7	 184	 55.93	 222	 60.49	 244	 67.03	 330	 75.00	 980	 65.33	 <0.0001	
			3+4	 158	 48.02	 189	 51.50	 188	 51.65	 262	 59.55	 797	 53.13	 0.0096	
			4+3	 26	 7.90	 33	 8.99	 56	 15.38	 68	 15.45	 183	 12.20	 0.0007	
8	 12	 3.65	 15	 4.09	 12	 3.30	 21	 4.77	 60	 4.00	 0.61	
9	or	10	 6	 1.82	 17	 4.63	 22	 6.04	 40	 9.09	 85	 5.67	 0.0002	
Pathological	stage	 		 		 		 		 		 		
	
		
	No	tumour	found	 1	 0.30	 0	 0.00	 0	 0.00	 2	 0.45	 3	 0.20	 NA	
pT2a	 121	 36.78	 55	 14.99	 38	 10.44	 24	 5.45	 238	 15.87	 <0.0001	
pT2b	 10	 3.04	 2	 0.54	 7	 1.92	 4	 0.91	 23	 1.53	 NA	
pT2c	 53	 16.11	 136	 37.06	 138	 37.91	 163	 37.05	 490	 32.67	 <0.0001	
pT3a	 125	 37.99	 147	 40.05	 150	 41.21	 193	 43.86	 615	 41.00	 0.41	
pT3b	 17	 5.17	 26	 7.08	 31	 8.52	 51	 11.59	 125	 8.33	 <0.0001	
pT4	 2	 0.61	 1	 0.27	 0	 0.00	 3	 0.68	 6	 0.40	 NA	
Nodal	Mets,	n	(%)	 		 		 		 		 		 		
	 	
		
					pNx	 139	 42.25	 74	 20.16	 124	 34.07	 130	 29.55	 467	 31.13	 NA	
pN0	 187	 98.42	 281	 95.90	 219	 91.25	 270	 87.10	 957	 92.64	 <0.0001	
pN1	 3	 1.58	 12	 4.10	 21	 8.75	 40	 12.90	 76	 7.36	 <0.0001	
Surgical	margin	status	 		 		 		
	 	
		
	Overall	-ve	 255	 77.51	 288	 78.47	 281	 77.20	 353	 80.23	 1177	 78.47	 0.72	
Overall	+ve	 74	 22.49	 79	 21.53	 83	 22.80	 87	 19.77	 323	 21.53	 0.72	
pT2	PSM	 22	 11.96	 17	 8.81	 17	 9.29	 12	 6.28	 68	 9.05	 0.076	
pT3a	PSM	 39	 31.20	 46	 31.29	 47	 31.33	 50	 25.91	 182	 29.59	 0.91	
pT3b	PSM	 11	 64.71	 15	 57.69	 19	 61.29	 22	 43.14	 67	 53.60	 0.60	
	
	
	
	
